КОРОНАРДЫН КУРЧ СИНДРОМУНА БӨЙРӨКТYН ИШИНИН БУЗУЛУШУ КОШУЛГАНДА ДАРЫЛОО ӨЗГӨЛӨЛYКТӨРY
Аннотация
Бул макалада коронардын курч синдромуна бөйрөктүн бузулушу кошулганда дарылоо өзгөчөлүктөрү каралат.
Ключові слова:
коронардык курч синдрому, бөйрөктүн өнөкөт илдети.Посилання
1. M. J. Sarnak, A. S. Levey, A. C. Schoolwertр et al. Kidney Disease as a Risk Factor for Development of Cardio-vascular Disease: A Statement From the American Heart As-sociation Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiol-ogy and Prevention. Circulation 2003; 42 (5): 1050-1065.
2. Kidney Disease: Improving Global Outcomes (KDI-GO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney In-ternational Supplements 2013; 3 (5): 259-305.
3. Г. Арутюнов, Т. Чернявская. Проблемы нефропротекции у пациентов с артериальной гипертонией. Значение показателя микроальбуминурии для врача общей практики. Артериальная гипертония 2005; 3: 2-7.
4. О. Кузьмин. Хроническая болезнь почек и состояние сердечно-сосудистой системы. Нефрология 2007; 11 (1): 28-29.
5. Е. Макеева, А. Шутов, В. Серов и др. Хроническая болезнь почек влияет на прогноз и стоимость стационарного лечения больных с хронической сердечной недостаточностью. Нефрология 2010; 14 (2): 21-55.
6. S. Spilner, S. Inverso, M. Cohen et al. Safety and ef-ficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. American Heart Journal 2003; 146 (1): 33-41.
7. J. Januzzi, C. Cannon, P. DiBattiste et al. Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). The American Journal of Cardiology 2002; 90 (11): 1246-1249.
8. C. Gibson, R. Dumaine, E. Gelfand et al. Associa-tion of glomerular filtration rate on presentation with subse-quent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13307 patients in five TIMI trials. European Heart Journal 2004; 25 (22): 1998-2005.
9. C. Gibson, D. Pinto, S. Murphy et al. Association of creatinine clearance on presentation in acute myocardial in-farction with subsequent mortality. Journal of the American College of Cardiology 2003; 42 (9): 1535-1543.
10. F. Rodrigues, R. Bruetto, U. Torres et al. Effects of kidney disease on acute coronary syndrome. Clinical Journal of the Society Nephrology 2010; 5 (8): 1530-1536.
11. Ronco C. Cardiorenal syndromes: definition and classification. Contributions to Nephrology 2010; 164: 33-38.
12. Kidney Disease: Improving Global Outcomes (KDI-GO) CKD Work Group. KDIGO 2012 Clinical Practice Guide-line for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements 2013; 3 (5):1-150.
13. D. Hasdai, S. Behar, L. Wallentin et al. A prospec-tive survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin: the Euro Heart Survey of Acute Coro-nary Syndromes. European Heart Journal 2002; 23 (15): 1190-1201.
14. I. Goldenberg, I. Subirana, V. Boyko et al. Relation between renal function and outcomes in patients with non-ST segment elevation acute coronary syndrome: real-world data from the European Public Health Outcome ResearchandIndi-cators Collection Project. Archives of Internal Medicine 2010; 170 (10): 888-895.
15. B. Franczyk-Skóra, A. Gluba, M. Banach et al. Pre-vention of sudden cardiac death in patients with chronic kidney disease. BMC Nephrology 2012; 13: 162.
16. Ю. Вялкина, С. Шалаев. Клиренс креатинина в долгосрочном прогнозировании риска сердечно-сосудистой смерти у больных острым коронарным синдромом без подъемов сегмента ST. Клиническая нефрология 2011; 2: 27-30.
17. W. Couser, M. Riella. World Kidney Day 2011 – Pro-tect your kidneys, save your heart. Archives of Medical Science 2011; 7 (1): 1-4.
18. R. van Domburg, S. Hoeks, G. Welten, et al. Renal insufficiency and mortality in patients with known or suspected coronary artery disease. Journal of the American Society of Nephrology 2008; 19 (1): 158-163.
19. J. Malyszko, H. Bachorzewska-Gajewska, J. Maly-szko, et al. Markers of kidney function in the elderly in relation to the new CKD-EPI formula for estimation of glomerular fil-tration rate. Archives of Medical Science 2011; 7 (4): 658-664.
20. Н. Мухин, Г. Арутюнов, В. Фомин. Альбуминурия – маркер поражения почек и риска сердечно-сосудистых осложнений. Клиническая нефрология 2009; 1: 5–10.
21. D. Nair, S. Mehta, D. Mikhailidis. Assessing renal function – searching for the perfect marker continues! Ar-chives of Medical Science 2011; 7 (4): 565-567.
22. W. Coats, S. Baig, M. Alpert, K. Aggarwal. Manage-ment of coronary artery disease in patients with chronic kidney disease. Advances in Peritoneal Dialysis 2009; 25: 125-128.
23. J. Collet, G. Montalescot, G. Agnelli et al. Non-ST segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. European Heart Journal 2005; 26 (21): 2285-2293.
24. S. James, A. Budaj, P. Aylward et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition andPatient Outcomes (PLATO) trial. Circulation 2010; 122 (11):1056-1067.
25. M. Kowalczyk, M. Banach, D. Mikhailidis et al. Ti-cagrelor: a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibi-tors? Medical Science Monitor 2009; 15 (12): MS24-30.
26. P. J. Best, S. R. Steinhubl, P. B. Berger et al. The ef-ficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney dis-ease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal 2008; 155 (4): 687-693.
27. B. Franczyk-Skóra, A. Gluba, M. Banach et al. Acute coronary syndromes in patients with chronic kidney disease. Current Vascular Pharmacology 2013; 11 (5): 758-767.
28. C. Hamm, J. Bassand, S. Agewall et al. ESC Com-mittee for Practice Guidelines. ESC Guidelines for the man-agement of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society ofCardiology (ESC). European Heart Journal 2011; 32 (23): 2999-3054.
29. Н. А. Мухин. Снижение скорости клубочковой фильтрации — общепопуляционный маркер неблагоприятного прогноза. Терапевтический архив 2007; 6: 5-10.
30. C. R. Swanepoel. Chronic kidney disease is a risk factor for cardiovascular disease. SA Heart Journal 2007; 4 (3): 38-43.
31. A. Mercando, H. Lai, W. Aronow et al. Reduction in atherosclerotic events: a retrospective study in an outpatient cardiology practice. Archives of Medical Science 2012; 8 (1): 57-62.
32. K. Szummer, P. Lundman, S. Jacobson et al. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. Journal of Internal Medicine 2010. 268 (1); 40–49.
33. C. Fox, P. Muntner, A. Chen et al. Acute Coronary Treatment and Intervention Outcomes Network registry. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network reg-istry. Circulation 2010; 121 (3): 357-365.
34. J. Rhee, S. Wiviott, B. Scirica et al. Clinical Features, Use of Evidence-Based Therapies, and Cardiovascular Out-comes Among Patients With Chronic Kidney Disease Follow-ing Non–ST-Elevation Acute Coronary Syndrome. Clinical Cardiology 2014; 37 (6): 350-356.
35. C. Medi, G. Montalescot, A. Budaj et al. Reperfusion in patients with renal dysfunction after presentation with ST-segment elevation or left bundle branch block: GRACE (Glob-al Registry of Acute Coronary Events). JACC: Cardiovascular Intervention 2009; 2 (1): 26-33.
36. C. Meisinger, A. Doring, H. Lowel. Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women form the general population. European Heart Journal 2006; 27 (10): 1245–1250.
37. L. Szczech, P. Best, E. Crowley et al. Outcomes of patients with chronic renal insufficiency in the bypass angio-plasty revascularization investigation. Circulation 2002; 105 (19): 2253– 2258.
38. P. McCullough, S. Soman, S. Shah et al. Risks associ-ated with renal dysfunction in patients in the coronary care unit. Journal of the American College of Cardiology 2000; 36 (3):679–684.
39. J. Beattie, S. Soman, K. Sandberg et al. Determinants of mortality after myocardial infarction in patients with ad-vanced renal dysfunction. American Journal of Kidney Diseases 2001; 37 (6): 1191–1200.
40. S. Coca, H. Krumholz, A. Garg et al. Underrepresen-tation of renal disease in randomized controlled trials of car-diovascular disease. JAMA 2006; 296 (11):1377– 1384.
41. А. Николаев, В. Ермоленко. Место блокаторов РАС в нефропротективной стратегии при хронической болезни почек. Нефрология и диализ 2012; 12 (1): 8-12.
42. H. Lai, W. Aronow, A. Mercando et al. Risk factor re-duction in progression of angiographic coronary artery dis-ease. Archives of Medical Science 2012; 8 (3): 444-448.
43. R. Wright, G. Reeder, C. Herzog et al. Acute myocar-dial infarction and renal dysfunction: a high-risk combination. Annals of Internal Medicine 2002; 137 (7): 563-570.
44. C. Baigent, M. Landray, C. Leaper et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases 2005; 45 (3): 473-484.
45. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarc-tion, and stroke in high risk patients. British Medical Journal 2002; 324 (7329): 71-86.
46. A. Berger, S. Duval, H. Krumholz. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acutemyocar-dial infarction. Journal of the American College of Cardiology 2003; 42 (2): 201-208.
47. A. Sciahbasi, R. Arcieri, M. Quarto et al. Impact of chronic aspirin and statin therapy on presentation of patients with acute myocardial infarction and impaired renal function. Preventive Cardiology 2010; 13 (1): 18-22.
48. D. Reddan, J. O’Shea, I. Sarembock et al. Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). American Journal of Cardiology 2003; 91 (1): 17-21.
49. R. Freeman, R. Mehta, W. Al Badr et al. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of gly-coprotein IIb/IIIa inhibitors. Journal of the American College of Cardiology 2003; 41 (5): 718-724.
50. P. Berger, P. Best, E. Topol et al. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. American Heart Journal 2005; 149 (5): 869-875.
51. A. Kirtane, G. Piazza, S. Murphy et al. Correlates of bleeding events among moderate- to high-risk patients under-going percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI- 30 trial. Journal of the American College of Cardiology 2006; 47 (12): 2374-2379.
52. K. Alexander, A. Chen, M. Roe et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005; 294 (24): 3108-3116.
53. S. Basra, P. Tsai, N. Lakkis. Antiplatelet and anti-thrombotic therapy in ACS patients with CKD: antiplatelet and antithrombotic drugs. Journal of the American College of Cardiology 2011; 58 (22): 2263-2269.
54. C. Torp-Pedersen, L. Kober. Effects of ACE inhibitor trandolapril on life expectancy of patients with reduced LVEF after acute myocardial infarction. TRACE Study Group. Tran-dolapril Cardiac Evaluation. Lancet 1999; 354 (9172): 9-12.
55. G. Dagenais, J. Pogue, K. Fox et al. Angiotensin-con-verting enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trial. Lancet 2006; 368 (9535): 581-588.
56. J. Mann, H. Gerstein, J. Pogue et al. Renal insuffi-ciency as a predictor of cardiovascular outcomes and the im-pact of ramipril: the HOPE randomized trial. Annals of Inter-nal Medicine 2001; 134(8): 629-636.
57. ONTARGET Investigators, S. Yusuf, K. Teo, J. Pogue et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. The New England Journal of Medicine 2008; 358 (15): 1547-1559.
58. J. Lopez-Sendon, K. Swedberg, J. McMurray et al. Expert consensus document on beta-adrenergic receptor blockers. European Heart Journal 2004; 25 (15): 1341-1362.
59. M. Stepien, M. Banach, D. Mikhailidis et al. Role and significance of statins in the treatment of hypertensive patients. Current Medical Research and Opinion 2009; 25 (8): 1995-2005.
60. C. Cannon, E. Braunwald, C. McCabe et al. Intensive versus moderate lipid lowering with statins after acute coro-nary syndromes. The New England Journal of Medicine 2004; 350 (15): 1495-1504.
61. N. Edwards, R. Steeds, C. Ferro et al. The treatment of coronary artery disease in patients with chronic kidney dis-ease. QJM 2006; 99 (11): 723-736.
62. V. Athyros, A. Hatzitolios, A. Karagiannis et al.; IM-PERATIVE Collaborative Group. IMproving the imPlemEnta-tion of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial intervention. The IMPERATIVE renal analysis. Archives of Medical Science 2011; 7 (6): 984-992.
63. M. Munar, H. Singh Drug dosing adjustments in pa-tients with chronic kidney disease. American Family Physician 2007; 75 (10):1487-1496.
R. Scarpioni, M. Ricardi, V. Albertazzi et al. Treat-ment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins. World Journal of Nephology 2012; 1 (6):184-194.
65. В. Моисеев, Н. Мухин, Ж. Кобалава и др. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардионефропротекции. Клиническая нефрология 2014; 2: 4-29.
66. B. Franczyk-Skóra, A. Gluba, M. Banach et al. Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease. Archives of Medical Science 2013; 9 (6): 1019-1027.
67. G. Marenzi, A. Cabiati, E. Assanelli. Chronic kidney disease in acute coronary syndromes. World Journal of Nephrology 2012; 1 (5): 134-145.
